Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure

NCT01972529 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01972529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01972529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2014
Completion date
February 27, 2017
Enrollment
231 (actual)
Sites
109

Conditions

As the registry lists them; a condition with its own page is linked.

thrombocytopenia associated with liver disease